Exclusive Asia-Pacific licensing agreement for Bejescin strengthens the company’s nephrology and autoimmune disease portfolio
Regulatory clearance strengthens company’s global footprint and expands access to the Australian animal healthcare market
The certification follows an inspection conducted by the Malta Medicines Authority between January 29, 2026, and February 3, 2026
The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
Starting January 1, 2027, Lilly’s Zepbound (tirzepatide), Mounjaro (tirzepatide), and orforglipron, if approved, will be available through participating Medicare Part D plans
The recommendation is based on new data from continuous safety monitoring of medicines in the EU
The approval is backed by data showing deep, durable responses and manageable tolerability
The accelerated review covers WCK 5222 for multiple critical infections
The move is expected to be crucial during health crises
Subscribe To Our Newsletter & Stay Updated
